Artesunate, a derivative of plant-extracted malaria drug artemisinin, was shown to reduce the formation of atherosclerotic plaques, acting through increased expression of KLF2 and LPL (lipoprotein lipase)—the central triglyceride hydrolyzing enzyme, which deficiency leads to atherosclerosis [86]. The gene discussed is KLF2; the disease is atherosclerosis.